Reference number : 236-2016-2017-Q4-00337, amendment number : , agreement type : G, recipient legal name : Venner, Christopher P, recipient country : CA, recipient province : AB, recipient city : Edmonton, recipient postal code : T6G 2E1, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 147354.0, agreement start date : 2017-03-01, agreement end date : 2020-02-29, description english : A randomized phase II trial of bortezomib-based therapy plus doxycycline vs. bortezomib-based chemotherapy plus standard supportive therapy in cardiac AL amyloidosis, description french : A randomized phase II trial of bortezomib-based therapy plus doxycycline vs. bortezomib-based chemotherapy plus standard supportive therapy in cardiac AL amyloidosis, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2016-17 to 2019-20), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2016-17 à 2019-20), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada